31P MRS Ischaemic Exercise Optimisation and COPD
Primary Purpose
Atrophy, Muscular
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
MRI scan
Sponsored by
About this trial
This is an interventional basic science trial for Atrophy, Muscular
Eligibility Criteria
Inclusion Criteria:
- Fit to safely tolerate procedures
- Male or female between 18 and 80 years of age
- If pre-menopausal female, non-pregnant on dipstick urinalysis
- Subject and responsible physician agree that the subject will be able to comfortably lie in scanning position in the scanner for up to 90 minutes
- Capable of giving written informed consent
- All four limbs are intact and free of disease
The following criteria apply to patients with COPD myopathy only:
- Established diagnosis of COPD with a disease classification of GOLD Stage II and above with suspected or established diagnosis of myopathy and/or COPD with low BMI (under 20 for men and under 19 for women) and/or MVC under 120% of the BMI.
- At least a 20 pack year history of smoking
- Resting oxygen saturation above 85% on room air
- Ambulant and not oxygen-dependent at rest or during mild exertion
Exclusion Criteria:
- Ineligible for MRI/MRS scanning in accordance to local MR safety regulations
- Any medical condition, acute or chronic, that will lead to potential discomfort when lying supine in the magnet for periods up to 90 min
- Any medical condition that will lead to potential discomfort with repetitive movement of the limb being tested in the scanner
- Subjects undergoing ischaemic/anaerobic 31P MRS must have no history of clinically significant peripheral vascular disease, abnormal blood clotting, deep vein thrombosis or pulmonary embolism or suspected clinically significant signs of limb vascular disease on screening examination.
- Subjects undergoing ischaemic/anaerobic 31P MRS must not have taken the oral contraceptive pill, hormone replacement therapy, or undergone anaesthesia within past 1 month, or have a history of recent prolonged immobility greater than 4 hours (e.g. air travel), or considered unfit in the opinion of the study physician
- Concurrent medical conditions known or suspected that in the opinion of the responsible physician could confound interpretation of results.
- A medical or psychiatric history that in the opinion of the responsible physician would risk safety of the subject or well-being of the subject.
The following criteria apply to control subjects and COPD patients participating in Part C of the study:
- Oxygen saturations below 85% on room air at rest, or significant desaturation on mild exertion.
- Current or recent (<4 weeks) infectious exacerbation of COPD requiring corticosteroid therapy at the time of screening or scanning visit day.
- Any significant medical illness other than COPD which, in the opinion of the study physician, may preclude participation or which by virtue of being associated with muscle weakness may cause distortion of the results (e.g. neuromuscular disease, severe heart failure &c).
- Control subjects with any history of regular smoking
Sites / Locations
- GSK Investigational Site
Arms of the Study
Arm 1
Arm Type
No Intervention
Arm Label
no treatment
Arm Description
MRI scans only
Outcomes
Primary Outcome Measures
level of skeletal muscle metabolism
ADP, ATP, PCr, Pi, and pH will be measured during rest, anaerobic exercise and recovery to determine muscle metabolism.
Secondary Outcome Measures
determine Markers of disease in patients with COPD-related myopathy
tests such as spirometry, muscle biopsy, muscle cross-sectional area CSA, muscle strength to indicate level of disease progression
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01476072
Brief Title
31P MRS Ischaemic Exercise Optimisation and COPD
Official Title
31P MRS Ischaemic Exercise Optimisation and COPD Myopathy Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
An MRI study to develop a reliable methodology for 31P MRS ischaemic exercise in order to obtain a consistent standard of measurement of muscle metabolism while maintaining an acceptable level of subject comfort and use optimised method to measure and compare metabolism in the biceps and quadriceps of patients with COPD-related myopathy and control subjects
Detailed Description
31P Magnetic Resonance Spectroscopy (31P MRS) is a non-invasive method to measure muscle metabolism during exercise. This protocol is intended to provide information for planning future clinical trials applying 31P MRS as an endpoint measure for proof of pharmacology studies with novel therapeutic molecules. Parts A & B of this study will refine imaging and exercise protocols for 31P MRS during brief periods of muscle ischaemia and will assess the test-retest variance. In Part C we will apply 31P MRS with aerobic exercise in a pilot study to estimate differences in skeletal muscle oxidative metabolism between age- and sex-matched control subjects and patients with myopathy associated with Chronic Obstructive Pulmonary Disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrophy, Muscular
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
75 (Actual)
8. Arms, Groups, and Interventions
Arm Title
no treatment
Arm Type
No Intervention
Arm Description
MRI scans only
Intervention Type
Other
Intervention Name(s)
MRI scan
Intervention Description
MRI scan only, methodology study with no other intervention
Primary Outcome Measure Information:
Title
level of skeletal muscle metabolism
Description
ADP, ATP, PCr, Pi, and pH will be measured during rest, anaerobic exercise and recovery to determine muscle metabolism.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
determine Markers of disease in patients with COPD-related myopathy
Description
tests such as spirometry, muscle biopsy, muscle cross-sectional area CSA, muscle strength to indicate level of disease progression
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Fit to safely tolerate procedures
Male or female between 18 and 80 years of age
If pre-menopausal female, non-pregnant on dipstick urinalysis
Subject and responsible physician agree that the subject will be able to comfortably lie in scanning position in the scanner for up to 90 minutes
Capable of giving written informed consent
All four limbs are intact and free of disease
The following criteria apply to patients with COPD myopathy only:
Established diagnosis of COPD with a disease classification of GOLD Stage II and above with suspected or established diagnosis of myopathy and/or COPD with low BMI (under 20 for men and under 19 for women) and/or MVC under 120% of the BMI.
At least a 20 pack year history of smoking
Resting oxygen saturation above 85% on room air
Ambulant and not oxygen-dependent at rest or during mild exertion
Exclusion Criteria:
Ineligible for MRI/MRS scanning in accordance to local MR safety regulations
Any medical condition, acute or chronic, that will lead to potential discomfort when lying supine in the magnet for periods up to 90 min
Any medical condition that will lead to potential discomfort with repetitive movement of the limb being tested in the scanner
Subjects undergoing ischaemic/anaerobic 31P MRS must have no history of clinically significant peripheral vascular disease, abnormal blood clotting, deep vein thrombosis or pulmonary embolism or suspected clinically significant signs of limb vascular disease on screening examination.
Subjects undergoing ischaemic/anaerobic 31P MRS must not have taken the oral contraceptive pill, hormone replacement therapy, or undergone anaesthesia within past 1 month, or have a history of recent prolonged immobility greater than 4 hours (e.g. air travel), or considered unfit in the opinion of the study physician
Concurrent medical conditions known or suspected that in the opinion of the responsible physician could confound interpretation of results.
A medical or psychiatric history that in the opinion of the responsible physician would risk safety of the subject or well-being of the subject.
The following criteria apply to control subjects and COPD patients participating in Part C of the study:
Oxygen saturations below 85% on room air at rest, or significant desaturation on mild exertion.
Current or recent (<4 weeks) infectious exacerbation of COPD requiring corticosteroid therapy at the time of screening or scanning visit day.
Any significant medical illness other than COPD which, in the opinion of the study physician, may preclude participation or which by virtue of being associated with muscle weakness may cause distortion of the results (e.g. neuromuscular disease, severe heart failure &c).
Control subjects with any history of regular smoking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
London
ZIP/Postal Code
W12 ONN
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
31P MRS Ischaemic Exercise Optimisation and COPD
We'll reach out to this number within 24 hrs